Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.

Akdag C., SAHIN S., BUTTINI F., BALDUCCI A., MONTANARI S., VURAL I., ...More

Drug development and industrial pharmacy, vol.43, pp.1378-1389, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 43
  • Publication Date: 2017
  • Doi Number: 10.1080/03639045.2017.1318902
  • Journal Name: Drug development and industrial pharmacy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1378-1389
  • Keywords: Dry powder inhaler, ciprofloxacin, levofloxacin, mucolytic, permeability, cystic fibrosis, PULMONARY DRUG-DELIVERY, CELL-LINE, CALU-3, LUNG, PHARMACOKINETICS, MICROSPHERES, TOLERABILITY, OPTIMIZATION, MOXIFLOXACIN, DEHYDRATION
  • Hacettepe University Affiliated: Yes